Effect of ursodeoxycholic acid in acute viral hepatitis

Journal of Clinical Gastroenterology

Volumn 28, Issue 3, 1999, Pages 254-

  Galsky, Jan ^a,c   Bansky, George ^a,b   Holubovâ, TaT'Ana ^a,b   König, Jaroslav ^a,b  

^a Kopa Melnïk Hospital   (Czech Republic)

^b National Laboratory for Viral Hepatitis   (Czech Republic)

^c Infectious Department   (Czech Republic)

Author keywords

Acute disease; Hepatitis b; Hepatitis drug treatment; Hepatitis, viral; Ursodeoxycholic acid

Indexed keywords

EID: 33744460524     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Simko V, Michaels S, Prego V. Ursodeoxycholic therapy in chronic liver disease: a metaanalysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gastroenterol 1994;89(3):392-8.
2. Guldutuna S, Leuschner U, Imhof M, Zimmer G. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid. Z Gastroenterol 1992;30(Suppl l):49-54.
3. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 3-year pilot study with a placebocontrolled study period. J Hepaiol 1994;20(l):57-64.
4. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19(5): 1149-56.
5. Attili AF, Rustical! A, Varriale M, Carli L, Repice AM, Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis: a 12-month double-blind, placebo-controlled trial. J Hepaiol 1994;20(3): 315-20.
6. Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical tnal.JHepatol 1993;19(3):459-64.
7. Nambu M, lijima T. Treatment of patients with chronic hepatitis using ursodeoxycholic acid. Trop Gastroenterol 1993;14(2):59-65.
8. Osuga T, Tanaka N, Matsuzaki Y, Aikawa T. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig Dis Sei 1989;34(Suppl 12):49S-51S.
9. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig D/îSdl985;30(7):642-9.
10. Poupon E, Poupon R, Baikau B, the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 12.330( 19): 1342-7.
11. Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22(3):759-66.
12. Stiehl A. Treatment of cholestatic liver diseases, the role of ursodeoxycholic acid. Z Gastroenterol 1992;30(10):743-7.
13. Nakamura K, Aoshima M, Tani M, et al. Effect of ursodeoxycholic acid (UDCA) therapy for compensatory liver cirrhosis on liver function tests and serum bile acid metabolism. Nippon Shokakityo Gakkai Zasshi 1992;89(12):2762-70.
14. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Effect of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990;98(4): 1044-50.
15. Cirillo NW, Zwas FR. Ursodeoxycholic acid in the treatment of chronic liver disease. Am J Gastroenterol 1994;89(9):1447-52.
16. van de Meeberg PC, van Erpecum KJ, van Berge-Henegomven GP. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol Suppl 1993;200:15-20.
17. Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994;121(3): 207-18.
18. Calmus Y, Poupon R. Ursodeoxycholic acid in the treatment of chronic cholestatic diseases. Biochemistry 1?91;73:1335-8.
19. Calmus Y, Gane P, Rouger P, et al. Hepatis expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Heparo/ogyl990;ll:12-15.
20. Heuman DM, Bajas RT- Ur.sodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106(5): 1333-41.
21. Takano S, Ito Y, Zokosuka O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20(3):558-64.
22. Wright TL. Chronic hepatitis B and C: what the status of drug therapy? Postgrad Med 1992;92(4):75-82.
23. de Moura MC, Velosa J, Pinto HC. Is there an alternative to alfainterferon in chronic hepatitis B? J Hepatol 1991;13(Suppl 1):S12-16.
24. Homann J, Petri F, Deltjer W, et al. Therapeutical effects of UDCA on acute virus hepatitis. Falk Symposium No. 54: Infectious Diseases of the Liver. Basel, October 12-14, 1989.
25. Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994;42(3):306-10.
26. Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol 1993;8(5): 470-5.
27. Kadayifci A, Savas MC, Arslan S, Gullu H. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B. J Clin Gastroenterol 1997;24(2):125-6.
28. Tanaka H, Makino Y, Miura T, et al. Ligang-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J Immunol 1996;156:1601-8.
29. Beuers U, Throckmorton DC, Anderson MS, et al. Tauroursocholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996;110:1553-63.
30. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Set USA 1994;91(9): 3764-8.
31. Ozer A, Khaoustov VI, Mearns M, et al. Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology 1996;110:1519-28.